ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©µËÎı󡢳º첨ºÍ³Ì·¼ÍŶÓÒÔºËÈÊΪÖÎÁưеãÍØÕ¹ÁË¡°ÀÏÒ©¡±rDNAת¼ÒÖÖÆ¼ÁCX5461µÄÐÂÓÃ;

¸å¼þȪԴ £ºÒ©Ñ§Ôº£¨ÉîÛÚ£© ±à¼­ £ºÖ£Áú·É¡¢Íõ¶¬Ã· ÔĶÁÁ¿ £º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±³Âºì²¨£©ºËÈÊÊÇϸ°ûºËÖÐÒ»¸öÖ÷ÒªµÄÑÇϸ°û½á¹¹£¬£¬£¬ÆäÖ÷Òª¹¦Ð§ÊÇת¼ºËÌÇÌåRNA (Ribosomal RNA, rRNA) ºÍ×é×°ºËÌÇÌå¾ÞϸÑÇ»ù¡£¡£¡£µ«½üÄêµÄÑо¿·¢Ã÷ºËÈÊ»¹¼ÓÈëÁ˶àÖÖÖ÷ÒªµÄÉúÎïѧÀú³Ì£¬£¬£¬ºÃ±Èϸ°ûÖÜÆÚµ÷¿Ø¡¢Ï¸°ûÐàÂõ¡¢Ï¸°ûÓ¦¼¤·´Ó³ÒÔ¼°ÒÅ´«ÐÔ¼²²¡µÈ¡£¡£¡£µ«ºËÈÊÊÇ·ñ¿ÉÒÔ×÷ΪҩÎï×÷Óðе㻹±£´æÕùÂÛ£¬£¬£¬ÏÖÔÚ»¹Ã»ÓÐÒÔºËÈÊΪ°ÐµãµÄÖÎÁÆÒ©Îï±»Åú×¼ÉÏÊС£¡£¡£

2021Äê3Ô£¬£¬£¬ngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©µËÎıó½ÌÊÚ¡¢³Âºì²¨¸±½ÌÊںͳ̷¼¸±½ÌÊÚÒÔÅäºÏͨѶ×÷ÕßÔÚEMBO Molecular Medicine (JCR 1Çø£¬£¬£¬Ó°ÏìÒò×Ó12.1)½ÒÏþÁËÌâΪ¡°NF45/NF90-mediated rDNA transcription provides a novel target for immunosuppressant development¡±µÄÎÄÕ (DOI: 10.15252/emmm.202012834)¡£¡£¡£¸ÃÑо¿·¢Ã÷Ò»¸öºËÈʶ¨Î»µÄÂѰ׸´ºÏÌåNF45/ NF90¿ÉÒÔͨ¹ýµ÷¿ØºËÌÇÌåDNA£¨Ribosomal DNA£¬£¬£¬ rDNA£©×ªÂ¼Ó°ÏìTϸ°ûµÄÔöÖ³ºÍ»î»¯¡£¡£¡£¾­µäµÄTϸ°û»î»¯ÐźÅͨ·Ϊ¡°calcineurin-NFAT¡±ÐźÅͨ·¡£¡£¡£ÔڻÐźŴ̼¤Ï£¬£¬£¬calcineurin (CaN)±»¼¤»î£¬£¬£¬CaN¶ÔNFAT È¥Á×Ëữ£¬£¬£¬NFAT´Óϸ°ûÖÊת¶¨Î»µ½Ï¸°ûºËÖУ¬£¬£¬²¢Á¬Ïµµ½IL-2Æô¶¯×ÓÇøÓòµÄARRE2ÐòÁÐÔª¼þÉÏ£¬£¬£¬¼¤»îIL-2µÈϸ°ûÒò×ÓµÄת¼£¬£¬£¬½ø¶ø¼¤»îTϸ°û¡£¡£¡£Æ÷¹ÙÒÆÖ²¿ªÕ¹ÖÁ½ñ£¬£¬£¬ÒÆÖ²Æ÷¹ÙµÄÉúÑÄ¡¢ÊÖÊõ¼°Êõºó´¦ÀíÒÑÈÕÒæ³ÉÊì,ÊÜÕß´æ»îÂÊÓÐËùÔö¸ß£¬£¬£¬µ«ÒÆÖ²ÇãÔþ·´Ó³ÈÔÈ»ÊÇÍþвÊÜÕߺã¾Ã´æ»îµÄÖ÷ÒªÒòËØ¡£¡£¡£ÏÖÔÚÆ÷¹ÙÒÆÖ²¿Æ³£ÓõĻ·æß¾úËØA¼°FK506¾ÍÊÇͨ¹ýÒÖÖÆ ¡°calcineurin-NFAT¡± Tϸ°û»î»¯ÐźÅͨ·Æð×÷Óᣡ£¡£¶øÔÚ´ËÏîÑо¿ÖУ¬£¬£¬Ñо¿Õß·¢Ã÷µ±Tϸ°û»î»¯Ê±£¬£¬£¬NFAT²»µ«ÔÚºËÖÊÖе÷¿ØIL-2µÈϸ°ûÒò×ӵıí´ï£¬£¬£¬Í¬Ê±²¿·ÖNFATÒ²»á½øÈëµ½ºËÈÊÖÐÓëNF45/NF90¸´ºÏÎïÏ໥×÷Ó㬣¬£¬Á¬ÏµTϸ°ûrDNA»ùÒòÆô¶¯×ÓÉϵÄARRE2-likeÐòÁУ¬£¬£¬Ð­Í¬Ôö½ørDNAת¼½ø¶ø¼¤»îTϸ°û(ͼ1)¡£¡£¡£½øÒ»²½Ñо¿·¢Ã÷ÔÚСÊóÐÄÔàºÍƤ·ôÒÆÖ²ÇãÔþÄ£×ÓÖУ¬£¬£¬ÒÔ¼°ÁÙ´²ÉöÒÆÖ²T ϸ°û½éµ¼µÄÇãÔþ·´Ó³£¨TCMR£©»¼ÕßµÄÑù±¾ÖÐrDNAת¼²úÆ·(pre-rRNA)µÄˮƽ¾ùÊÇÉý¸ßµÄ¡£¡£¡£¾Ý´Ë£¬£¬£¬Ñо¿Õß½«Ò»ÖÖrDNAÌØÒìÐÔת¼ÒÖÖÆ¼ÁCX5461Ó¦ÓÃÔÚСÊ󯤷ôºÍÐÄÔàÒÆÖ²Ä£×ÓÖУ¬£¬£¬¾ªÏ²µÄ·¢Ã÷CX5461Ïà¹ØÓÚÁÙ´²³£ÓÃÒ©ÎïFK506Äܹ»¸üÓÐÓÃÑÓÉìÒÆÖ²ÎïµÄ´æ»îʱ¼ä£¬£¬£¬²¢ÇÒ¾ßÓиüµÍµÄ¶¾¸±×÷Óᣡ£¡£CX5461ÊÇÉúÎïÖÆÒ©¹«Ë¾Senhwa BiosciencesÓÚ2020Äê±»FDAÅú×¼¿É¿ªÕ¹ÓÃÓÚÖÎÁÆÐ¯´øBRCA2»òPALB2Í»±äµÄʵÌåÁö»¼ÕßIbÆÚÁÙ´²ÊÔÑéµÄÒ»¸öfirst-in-classÒ©Îï¡£¡£¡£×ÛºÏÒÔÉÏ£¬£¬£¬´ËÑо¿Õ¹ÏÖÁËÒ»ÖÖTϸ°û»î»¯µÄȫзÖ×Ó»úÖÆ£¬£¬£¬·¢Ã÷Á˺ËÈÊ¿É×÷ΪÃâÒßÒÖÖÆ¼Á¿ª·¢µÄае㣬£¬£¬²¢Àֳɽ«Ò»¸ö¿¹°©¡°ÀÏÒ©¡±CX5461µÄ˳Ӧ֢À©Õ¹µ½ÃâÒßÒÖÖÆµÄÁìÓò¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ1. NFATºÍNF45 / NF90ЭͬÔö½ørDNAת¼ºÍTϸ°û»î»¯µÄʾÒâͼ

¿ËÈÕ£¬£¬£¬¸ÃÍŶӽøÒ»²½Î§ÈƺËÈÊÕâÒ»°Ðµã£¬£¬£¬ÁªºÏÇ廪´óѧ»ÆÀ´Ç¿½ÌÊÚÍŶÓÔÚActa Pharmaceutica Sinica B (JCR 1Çø£¬£¬£¬Ó°ÏìÒò×Ó11.4)ÉϽÒÏþÁËÌâΪ¡°PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-mutant leukemia¡±µÄÎÄÕ£¨https://doi.org/10.1016/j.apsb.2021.10.025£©¡£¡£¡£Ìá³öÁËÕë¶ÔPHF6Í»±äÐͰ×Ѫ²¡µÄ¸öÐÔ»¯ÖÎÁÆ·½°¸¡£¡£¡£Ö²ÎïͬԴ½á¹¹ÓòÖ¸ÂѰ×6£¨Plant homeodomain finger protein 6, PHF6£©µÄ·¢Ã÷Ô´ÓÚ¶Ô¡°²®-¸£-À³ÈýÊÏ×ÛºÏÖ¢£¨Borjeson-Forssman-Lehmann syndrome, BFLS£©¡±µÄÑо¿¡£¡£¡£BFLSÊÇÒ»ÖÖXȾɫÌåÁ¬ËøµÄ¼Ò×åÒÅ´«ÐÔ¼²²¡£¬£¬£¬Æäµä·¶Ö¢×´ÎªÖжȻòÖØ¶ÈÖÇÁ¦·¢Óý³ÙÖͺÍÉíÌå»ûÐΡ£¡£¡£Ëæºó£¬£¬£¬¶à¸öÑо¿±¨µÀPHF6µÄÍ»±äÓëTϸ°û¼±ÐÔÁܰÍϸ°û°×Ѫ²¡£¡£¡£¨T-cell acute lymphoblastic leukemia£¬£¬£¬T-ALL£©ºÍ¼±ÐÔËèϵ°×Ѫ²¡£¡£¡£¨acute myeloid leukemia£¬£¬£¬AML£©µÄ±¬·¢ºÍ¿ªÕ¹Ò²Ç×½üÏà¹Ø¡£¡£¡£Ç°ÆÚÑо¿Åú×¢PHF6ÊÇÒ»¸öϸ°ûºËÈʶ¨Î»ÂѰ×£¬£¬£¬Òò´ËÕ¹ÏÖPHF6ÔÚºËÈÊÖÐʩչºÎÖÖ¹¦Ð§ÒÔ¼°ÆäÏêϸ·Ö×Ó»úÖÆ½«ÄÜÔö½øÎÒÃǶ԰×Ѫ֢±¬·¢µÄÃ÷È·£¬£¬£¬Í¬Ê±ÎªÔ¤·ÀºÍÖÎÁÆPHF6Ïà¹ØµÄ°×Ѫ²¡ÌṩеÄ˼Ð÷ºÍÒªÁì¡£¡£¡£

ÔÚÕâÏîÊÂÇéÖУ¬£¬£¬Ñо¿Õß·¢Ã÷PHF6¾ßÓÐÁ½¸ö·Çµä·¶µÄPHD½á¹¹Óò£¬£¬£¬¿ÉÒԽ鵼ÆäÓëºËÈÊȾɫÖÊ×éÂѰ×ÉϵÄH3K9me3ºÍH3K27me1Á¬Ïµ£¬£¬£¬²¢½«×éÂѰ׼׻ù×ªÒÆÃ¸SUV39H1ÕÐļµ½ºËÈÊÖУ¬£¬£¬Î¬³ÖºËÈÊrDNA»ùÒò×ùλȾɫÖʵÄÒìȾɫÖÊ״̬£¬£¬£¬´Ó¶øÒÖÖÆrDNA»ùÒòµÄת¼ºÍºËÌÇÌåµÄ×é×°¡£¡£¡£PHF6µÄÇóýµ¼ÖÂSUV39H1ÏòrDNA»ùÒòλµãµÄÕÙļïÔÌ­£¬£¬£¬µ¼ÖºËÈÊÇøÓò×éÂѰ×H3K9me3ˮƽ½µµÍ£¬£¬£¬²¢Ôö½ørDNAת¼¡£¡£¡£Ñо¿ÕßÒ²¿¼²ìÁ˶àÖÖPHF6ÁÙ´²Í»±äÌåµÄ¹¦Ð§£¬£¬£¬·¢Ã÷ÕâЩͻ±äÌåµÄºËÈʶ¨Î»ÄÜÁ¦»òʶ±ðºÍÁ¬ÏµºËÈÊÇøÓòH3K9me3µÄÄÜÁ¦Ï÷Èõ£¬£¬£¬ÒÔÖÁÓÚÆäÕÐļSUV39H1µÄÄÜÁ¦½µµÍ£¬£¬£¬µ¼ÖÂrDNAת¼»îÐÔÔöÌí¡¢ÌåÍâ°×Ѫ²¡Ï¸°ûÔöÖ³ºÍÌåÄÚСÊó°×Ѫ²¡ÒìÖÖÒÆÖ²ÎïÉú³¤£¨Í¼2£©¡£¡£¡£¸üÖ÷ÒªµÄÊÇ£¬£¬£¬ÔÚPHF6Í»±äµÄÁÙ´²AML»¼ÕßÑù±¾ÖÐÒ²ÊӲ쵽rRNAǰÌå·Ö×ӵıí´ïˮƽÏÔÖøÉý¸ß£¬£¬£¬½øÒ»²½Ö¤ÊµÎúÌåÍâÑо¿Ð§¹û¡£¡£¡£´ó¼ÁÁ¿°¢ÌǰûÜÕÊÇÖÎÁÆAML×î³£ÓõÄÖÎÁÆ·½°¸£¬£¬£¬µ«³£ÓÉÓÚAMLϸ°û¶ÔÆäÄÍÒ©ÐÔÒÔ¼°´ó¼ÁÁ¿¸øÒ©Ôì³ÉµÄ»¼Õß²»ÄÍÊܶøÊ¹µÃÖÎÁÆÊ§°Ü¡£¡£¡£±¾Ñо¿·¢Ã÷CX5461Äܹ»ÏÔÖø½µµÍPHF6¹¦Ð§È±Ê§µÄU937 AMLϸ°û¶Ô°¢ÌǰûÜÕµÄÄÍÒ©ÐÔ¡£¡£¡£ ×ÜÖ®£¬£¬£¬´ËÑо¿Õ¹ÏÖÁËPHF6 ½«¼×»ù×ªÒÆÃ¸ SUV39H1 ÕÙļµ½°×Ѫ²¡µÄºËÈÊÇøÓò´Ó¶øÒÖÖÆrDNAת¼µÄ·Ö×Ó»úÖÆ£¬£¬£¬Í¨¹ý¸Ã»úÖÆÎª PHF6 Í»±äÐͰ×Ѫ²¡ÌṩÁËÒ»ÖÖÓÐÔ¶¾°µÄ¸öÐÔ»¯¾«×¼ÖÎÁÆ·½°¸¡£¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ2. PHF6 ʶ±ðºÍÁ¬ÏµºËÈÊÇøÓò×éÂѰ×H3K9me3£¬£¬£¬ÕÐļ¼×»ù»¯×ªÒÆÃ¸SUV39H1 ½ø¶øÒÖÖÆ rDNA ת¼µÄʾÒâͼ

¸ÃÁ½ÏîÑо¿ÊÂÇé»ñµÃÁ˹ú¼Ò×ÔÈ»¿ÆÑ§ÃæÉÏÏîÄ¿¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿ºÍÉîÛÚÊпƴ´Î¯»ù´¡Ñо¿ÖصãÏîÄ¿µÄÖ§³Ö¡£¡£¡£

¸ÃÍŶÓÒÀÍÐngµç×ÓÓÎϷҩѧԺ£¨ÉîÛÚ£©Ò©Àíѧѧ¿Æ£¬£¬£¬ÒÑÀֳɽ¨ÉèÏȽøµÄ¸ßͨÁ¿ÒÅ´«ÎÄ¿âɸѡÊÖÒÕÆ½Ì¨£¨CRISPR pooled gRNA libraries)£¬£¬£¬²¢Ê¹ÓôËÊÖÒÕÕ¹ÏÖºÍÅжÏÁ˶à¸öÃâÒߺÍÖ×Áö¼²²¡µÄеÄÖÎÁưе㣬£¬£¬ÍØÕ¹Á˶à¸ö¡°ÀÏÒ©¡±µÄÐÂÓÃ;¡£¡£¡£½üÈýÄêÏà¹ØÐ§¹û»®·ÖÔÚCell Death & Differentiation £¨2021£©£¬£¬£¬The Journal of Pathology £¨2020£©ºÍ Nature Communications£¨2019£©µÈÔÓÖ¾ÉϽÒÏþ¡£¡£¡£

ÂÛÎÄÁ´½Ó £ºhttps://doi.org/10.1016/j.apsb.2021.10.025

¡¾ÍøÕ¾µØÍ¼¡¿